These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16432693)

  • 41. Decreased synaptic plasticity in the medial prefrontal cortex underlies short-term memory deficits in 6-OHDA-lesioned rats.
    Matheus FC; Rial D; Real JI; Lemos C; Ben J; Guaita GO; Pita IR; Sequeira AC; Pereira FC; Walz R; Takahashi RN; Bertoglio LJ; Da Cunha C; Cunha RA; Prediger RD
    Behav Brain Res; 2016 Mar; 301():43-54. PubMed ID: 26707254
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Automated gait analysis in bilateral parkinsonian rats and the role of L-DOPA therapy.
    Westin JE; Janssen ML; Sager TN; Temel Y
    Behav Brain Res; 2012 Jan; 226(2):519-28. PubMed ID: 22008381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
    Machado-Filho JA; Correia AO; Montenegro AB; Nobre ME; Cerqueira GS; Neves KR; Naffah-Mazzacoratti Mda G; Cavalheiro EA; de Castro Brito GA; de Barros Viana GS
    Behav Brain Res; 2014 May; 264():116-25. PubMed ID: 24525422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activation of 5-HT₁A receptors in the medial subdivision of the central nucleus of the amygdala produces anxiolytic effects in a rat model of Parkinson's disease.
    Sun YN; Wang T; Wang Y; Han LN; Li LB; Zhang YM; Liu J
    Neuropharmacology; 2015 Aug; 95():181-91. PubMed ID: 25797491
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of gray matter atrophy following 6-hydroxydopamine lesion of the nigrostriatal system.
    Westphal R; Sumiyoshi A; Simmons C; Mesquita M; Wood TC; Williams SC; Vernon AC; Cash D
    Neuroscience; 2016 Oct; 334():166-179. PubMed ID: 27506141
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Methylparaben protects 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and improved behavioral impairments in mouse model of Parkinson's disease.
    Kopalli SR; Noh SJ; Koppula S; Suh YH
    Neurotoxicology; 2013 Jan; 34():25-32. PubMed ID: 23068419
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sexually dimorphic postural adjustments during vertical behaviour are altered in a unilateral 6-OHDA rat model of Parkinson's disease.
    Field EF; Metz GA; Pellis SM; Whishaw IQ
    Behav Brain Res; 2006 Nov; 174(1):39-48. PubMed ID: 16930735
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
    Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
    Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circadian dysfunction in a rotenone-induced parkinsonian rodent model.
    Lax P; Esquiva G; Esteve-Rudd J; Otalora BB; Madrid JA; Cuenca N
    Chronobiol Int; 2012 Mar; 29(2):147-56. PubMed ID: 22324553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Zolpidem ameliorates motor impairments in the unilaterally 6-hydroxydopamine-lesioned rat.
    Assini R; Abercrombie ED
    Eur J Neurosci; 2018 Aug; 48(3):1896-1905. PubMed ID: 30019535
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
    Inden M; Kitamura Y; Kondo J; Hayashi K; Yanagida T; Takata K; Tsuchiya D; Yanagisawa D; Nishimura K; Taniguchi T; Shimohama S; Sugimoto H; Akaike A
    J Neurochem; 2005 Nov; 95(4):950-61. PubMed ID: 16135081
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High frequency stimulation of subthalamic nucleus results in behavioral recovery by increasing striatal dopamine release in 6-hydroxydopamine lesioned rat.
    He Z; Jiang Y; Xu H; Jiang H; Jia W; Sun P; Xie J
    Behav Brain Res; 2014 Apr; 263():108-14. PubMed ID: 24462728
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Motor activity-induced dopamine release in the substantia nigra is regulated by muscarinic receptors.
    Andersson DR; Björnsson E; Bergquist F; Nissbrandt H
    Exp Neurol; 2010 Jan; 221(1):251-9. PubMed ID: 19944096
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The 6-OHDA mouse model of Parkinson's disease - Terminal striatal lesions provide a superior measure of neuronal loss and replacement than median forebrain bundle lesions.
    Bagga V; Dunnett SB; Fricker RA
    Behav Brain Res; 2015 Jul; 288():107-17. PubMed ID: 25841616
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
    Carvalho MM; Campos FL; Coimbra B; Pêgo JM; Rodrigues C; Lima R; Rodrigues AJ; Sousa N; Salgado AJ
    Mol Neurodegener; 2013 Apr; 8():14. PubMed ID: 23621954
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Attenuation by Nardostachys jatamansi of 6-hydroxydopamine-induced parkinsonism in rats: behavioral, neurochemical, and immunohistochemical studies.
    Ahmad M; Yousuf S; Khan MB; Hoda MN; Ahmad AS; Ansari MA; Ishrat T; Agrawal AK; Islam F
    Pharmacol Biochem Behav; 2006 Jan; 83(1):150-60. PubMed ID: 16500697
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Circadian rhythm of drinking and running-wheel activity in rats with 6-hydroxydopamine lesions of the ventral tegmental area.
    Isobe Y; Nishino H
    Brain Res; 2001 Apr; 899(1-2):187-92. PubMed ID: 11311879
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of Parkinson's disease.
    Fifel K; Dkhissi-Benyahya O; Cooper HM
    Chronobiol Int; 2013 Jul; 30(6):741-55. PubMed ID: 23758587
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease.
    Fine JM; Forsberg AC; Renner DB; Faltesek KA; Mohan KG; Wong JC; Arneson LC; Crow JM; Frey WH; Hanson LR
    Brain Res; 2014 Jul; 1574():96-104. PubMed ID: 24928620
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early use of oleanolic acid provides protection against 6-hydroxydopamine induced dopamine neurodegeneration.
    Mabandla MV; Nyoka M; Daniels WM
    Brain Res; 2015 Oct; 1622():64-71. PubMed ID: 26111646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.